Tsubota Laboratory Incorporated
Research Tsubota Laboratory Incorporated (4890.T) on Bullrun: market cap JPY 6.65B. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- Ticker4890.T
- ExchangeTSE
- CountryJapan
- SectorHealthcare
- IndustryMedical Devices
- CurrencyJPY
- Market capJPY 6.65B
- Financial periodFY2026
- RevenueJPY 200.02M
- Revenue growth-85.3%
- Net income-JPY 761.82M
- Free cash flow-JPY 586.61M
- Gross margin65.8%
Valuation Snapshot
latest market cap is JPY 6.65B.
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2026 | JPY 200.02M | -JPY 761.82M | -JPY 586.61M | 65.8% | -29.58 | JPY 969.85M | JPY 69.21M | JPY 863.86M |
| FY2025 | JPY 1.36B | JPY 205.77M | -JPY 336.47M | 86.7% | 7.92 | JPY 1.54B | JPY 90.38M | JPY 1.59B |
| FY2024 | JPY 673.53M | -JPY 641.32M | -JPY 313.35M | 3.2% | -5.15 | JPY 1.88B | JPY 116.90M | JPY 1.37B |
| FY2023 | JPY 954.69M | JPY 90.18M | -JPY 20.27M | 75.3% | 3.52 | JPY 2.16B | JPY 139.34M | JPY 1.95B |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-10-18 | JPY 6.65B | n/a | n/a | 0 |
Dividend history
Latest trailing dividend snapshot: annual dividend/share 0 JPY.
About Tsubota Laboratory Incorporated
Tsubota Laboratory Incorporated engages in the development and sale of pharmaceuticals and medical devices for the treatment of myopia, dry eyes, presbyopia, and brain diseases in Japan, China, France, and internationally. The company was incorporated in 2012 and is headquartered in Tokyo, Japan.
Related stock research
Other Healthcare stocks
Frequently asked questions
What is Tsubota Laboratory Incorporated's market cap?
Tsubota Laboratory Incorporated's market capitalization is JPY 6.65B.
What does Tsubota Laboratory Incorporated do?
Tsubota Laboratory Incorporated engages in the development and sale of pharmaceuticals and medical devices for the treatment of myopia, dry eyes, presbyopia, and brain diseases in Japan, China, France, and internationally. The company was incorporated in 2012 and is headquartered in Tokyo, Japan.